CD300a anticorps

N° du produit ABIN2665985

Cet anticorps anti-CD300a est un anticorps Rat Monoclonal détectant CD300a dans FACS, IHC et IF. Adapté pour Souris.

Aperçu rapide pour CD300a anticorps (ABIN2665985)

Antigène: CD300a (CD300A)

Reactivité: Souris

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp CD300a est non-conjugé

Application: Flow Cytometry (FACS), Immunohistochemistry (IHC), Immunofluorescence (IF)

Clone: TX41

Détail du produit anti-CD300a anticorps

Marque: Ultra-LEAF™

Purification: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.

Stérilité: 0.2 μm filtered

niveau d'endotoxine:

Endotoxin level is <0.01 EU/μg of the protein (<0.001 ng/μg of the protein) as determined by the LAL test.

Isotype: IgG2a kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 1.0 mg/mL

Agent conservateur: Azide free

Conseil sur la manipulation: This Ultra-LEAF™ solution contains no preservative, handle under aseptic conditions

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur CD300a

Antigène: CD300a (CD300A)

Autre désignation: CD300a

Sujet: CD300 receptors are a group of type I transmembrane proteins, which belong to the Ig superfamily. In mice, nine members have been reported with different nomenclature systems, such as myeloid-associated Ig-like receptor (MAIR), leukocyte mono-Ig-like receptor (LMIR), DC-derived Ig-like receptor (DIgR), and CMRF-35-like molecule (CLM). The CD300 Molecules act as either activating or inhibitory receptors through interactions with adaptor molecules, such as PAD12, DAP10, and FcRγ. CD300a is an inhibitory receptor that is mainly expressed on peripheral eosinophils, mast cells, neutrophils, dendritic cells, macrophages, and some B cells. Cross-linking CD300a by an antibody can induce phosphorylation of tyrosine residues in the cytoplasmic domain, which results in recruitment of phosphatases SHIP, SHP1 and SHP2 and inhibition of cell activation.

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process